SGLT2 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2021

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 143 people · 2021

Randomised comparison

Probably lowered glycemic control

−0.77percentage points−0.98 to −0.57

As reported

difference −0.77 %, 95% CI −0.98 to −0.57

One number in the abstract

the abstract, start to end

placebo: least squares mean difference -0.77% (95% confidence interval

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.77−0.98 to −0.57
SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

8 papers cite it

2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 34033212